Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.47 |
| ▸ | IDH2 | P48735 | 3/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 4/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1410372 | 1.00 | DPP4 (0.50) | DPP4ADRB1NOTUMIDH2FFAR4 | |
| SCHEMBL1409363 | 1.00 | DPP4 (0.50) | DPP4ADRB1NOTUMIDH2FFAR4 | |
| SCHEMBL14092978 | 0.92 | FFAR4 (0.49) | DPP4ADRB1NOTUMIDH2FFAR4 | |
| SCHEMBL1410379 | 0.91 | FFAR4 (0.48) | DPP4ADRB1NOTUMIDH2FFAR4 | |
| SCHEMBL2938821 | 0.91 | DPP4 (0.46) | DPP4ADRB1NOTUMIDH2FFAR4 | |
| SCHEMBL17491541 | 0.89 | DPP4 (0.42) | DPP4ADRB1NOTUMIDH2FFAR4 | |
| SCHEMBL10104300 | 0.89 | FFAR4 (0.49) | DPP4ADRB1NOTUMIDH2FFAR4 | |
| SCHEMBL1410094 | 0.89 | FFAR4 (0.50) | DPP4ADRB1NOTUMIDH2FFAR4 | |
| SCHEMBL1410728 | 0.89 | DPP4 (0.42) | DPP4ADRB1NOTUMIDH2FFAR4 | |
| SCHEMBL14117187 | 0.85 | DPP4 (0.48) | DPP4ADRB1NOTUMIDH2FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295406-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-8338622-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2295406-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | NES, BMI1, DOT1L | DPP4 1356/4885ADRB1 2484/4885NOTUM 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.